Mineralys Therapeutics, Inc., a Philadelphia, PA-based clinical-stage biopharmaceutical company committed to developing a novel therapy for the treatment of hypertension, closed a $118m Series B financing.
Andera Partners and RA Capital Management facilitated the round. Participation from new investors included RTW Investments (RTW Investments), Rock Springs Capital, SR One Capital Management Sectoral Asset Management and Boulder Ventures. Adams Street Partners and Samsara BioCapital were among the existing investors. As part of the Series B financing, Olivier Litzka, PhD, Partner, Andera Partners and Derek DiRocco, Partner, RA Capital Management will join the Mineralys Board of Directors.
The company intends to use the funds to continue development of MLS-101 which is a highly selective inhibitor of aldosterone synthase. Target-HTN is a Phase 2 clinical trial that is currently evaluating MLS-101 in patients with uncontrolled hypertension.
Founded by Catalys Pacific and led by Jon Congleton, Chief Executive Officer, and BT Slingsby MD, PhD, MPH, Founder & Executive Chairman, Mineralys Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel therapy for the treatment of hypertension. The company’s goal is to develop MLS-101 to help manage hypertension. MLS 101, licensed by Mitsubishi Tanabe Pharma Corporation is a powerful aldosterone-synase inhibitor being tested for hypertension.